RxDoctor Payments DataLook up a doctor →

Jennifer Drake, DO

Clinical Neurophysiology · Canton, OHNPI 1437367570

Payments from drug & device makers

$25,252in general payments, 2019–2025

Across 982 payments — averaging $25.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$8K
  • AbbVie$3K
  • UCB, Inc.$1K
  • SK Life Science, Inc.$866
  • Novartis$811
  • Amgen$693
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$1501%
  • Food & beverage$16,91598%
  • Education$2231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB SA2$7,964
AbbVie(2 entities)197$3,097
UCB, Inc.45$1,211
SK Life Science, Inc.49$866
Novartis63$811
Amgen(2 entities)43$693
AstraZeneca34$674
EMD Serono, Inc.42$637
Jazz Pharmaceuticals Inc.24$525
Pfizer40$518
Sanofi26$513
Harmony Biosciences LLC21$483
Neurocrine Biosciences, Inc.24$447
Lilly USA, LLC21$426
Genentech USA, Inc.30$399
Eisai Inc.18$336
Acadia Pharmaceuticals Inc17$327
TG Therapeutics, Inc.17$318
Lundbeck LLC14$309
Kyowa Kirin, Inc.15$304
Johnson & Johnson(2 entities)12$285
Avadel CNS Pharmaceuticals, LLC12$256
Argenx US, Inc.9$213
Sunovion Pharmaceuticals Inc.17$208
E.r. Squibb & Sons, L.L.C.6$208
Xeris Pharmaceuticals, Inc.11$200
Axsome Therapeutics, Inc.11$200
Teva Pharmaceuticals USA, Inc.14$191
Neurelis, Inc.11$191
Bristol Myers Squibb10$162
Vanda Pharmaceuticals Inc.8$162
Biohaven Pharmaceuticals, Inc.8$156
Livanova USA, Inc.2$134
Sanofi Pasteur Inc.7$129
GE HealthCare10$117
Biohaven Pharmaceutical Holding Company Ltd.6$113
Amneal Pharmaceuticals LLC6$103
Sumitomo Pharma America, Inc.8$97
Takeda Pharmaceuticals U.S.A., Inc.4$95
Supernus Pharmaceuticals, Inc.4$85
Impel Pharmaceuticals Inc.5$83
Otsuka America Pharmaceutical, Inc.4$72
Tanabe Pharma America, Inc.4$66
Acorda Therapeutics, Inc4$57
Impel Pharmaceuticals LLC3$56
Strongbridge US Inc.4$51
Grifols USA, LLC2$47
Inspire Medical Systems, Inc.1$46
Biogen3$41
Avanir Pharmaceuticals, Inc.3$41
CSL Behring2$37
Scilex Pharmaceuticals Inc.2$34
Cycle Pharmaceuticals Inc2$34
Aquestive Therapeutics, Inc.2$34
Mallinckrodt Hospital Products Inc.2$32
Alnylam Pharmaceuticals Inc.1$31
Catalyst Pharmaceuticals, Inc.2$31
Greenwich Biosciences, Inc.2$30
Bausch Health US, LLC2$29
Collegium Pharmaceutical, Inc.2$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Ohioto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$121,907
Medicare patients
479
Services billed
2,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HetliozTasimelteon15$334,621
NuplazidPimavanserin Tartrate18$90,525
XcopriCenobamate66$79,827
FycompaPerampanel36$49,765
AptiomEslicarbazepine Acetate31$44,114
Nurtec OdtRimegepant Sulfate37$41,550
OnfiClobazam12$38,903
LamictalLamotrigine21$33,896
Oxtellar XrOxcarbazepine38$30,404
BriviactBrivaracetam20$29,677
Ajovy AutoinjectorFremanezumab-Vfrm25$22,009
UbrelvyUbrogepant18$20,432
Levetiracetam520$19,229
TrileptalOxcarbazepine27$17,402
QuliptaAtogepant16$16,716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Vanda Pharmaceuticals Inc.Hetlioz$162$334,62115 claims
Acadia Pharmaceuticals IncNuplazid$327$90,52518 claims
SK Life Science, Inc.Xcopri$866$79,82766 claims
Eisai Inc.Fycompa$336$49,76536 claims
PfizerNurtec Odt, Dilantin, Dilantin$518$49,36885 claims
Sunovion Pharmaceuticals Inc.Aptiom$208$44,11431 claims
AbbVieUbrelvy, Qulipta, Namzaric$3,097$43,78946 claims
Lundbeck LLCOnfi$309$38,90312 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$85$30,40438 claims
UCB, Inc.Briviact$1,211$29,67720 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$95$4,22111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Ohioon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →